The 20 Best Salpingo-Oophorectomy Doctors Near Me

Find the Experts and Specialists who perform Salpingo-Oophorectomy

OverviewFind a DoctorLatest AdvancesClinical Trials
Kevin M. Holcomb
Distinguished in Salpingo-Oophorectomy

Dr. Kevin M. Holcomb

Oncology
Northwell Health
Northwell Health Physician Partners Gynecologic Oncology At New Hyde Park
9 Vermont Drive, 1st Floor, 
New Hyde Park, NY 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Salpingo-Oophorectomy
Northwell Health
Northwell Health Physician Partners Gynecologic Oncology At New Hyde Park
9 Vermont Drive, 1st Floor, 
New Hyde Park, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Holcomb is an Oncologist in New Hyde Park, New York. Dr. Holcomb is rated as a Distinguished provider by MediFind in Salpingo-Oophorectomy. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Salpingo-Oophorectomy, and Lymphadenectomy.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Salpingo-Oophorectomy.

Graduate Institution
New York Medical College
Residency
New York Presbyterian Hospital-Weill Cornell
Specialties
Oncology
Licenses
Obstetrics & Gynecology in NY
Board Certifications
American Board Of Obstetrics & Gynecology
American Board Of Obstetrics & Gynecology-Gynecologic Oncology
Fellowships
State University of NY Health Science Center/Brooklyn
Hospital Affiliations
Long Island Jewish Medical Center
Long Island Jewish Forest Hills
Hofstra/Northwell School Of Medicine/Nursing
North Shore University Hospital
Katz Institute For Women's Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Northwell Health Physician Partners Gynecologic Oncology at New Hyde Park
9 Vermont Drive, 1st Floor, New Hyde Park, NY 11042
Call: 516-812-3740

Additional Areas of Focus

Dr. Holcomb has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Vaginal Cancer
Vulvar Cancer
Cervical Cancer
Gestational Trophoblastic Disease
Ovarian Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Clinical Utility of a Web-based Tool for Collection of Family Health History and Risk-assessment in Patients Presenting to a Gynecologic Oncology Clinic
Clinical Utility of a Web-based Tool for Collection of Family Health History and Risk-assessment in Patients Presenting to a Gynecologic Oncology Clinic
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Other
Study Phase: Not Applicable
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Enrollment Status: Terminated
Publish Date: June 14, 2022
Intervention Type: Biological, Procedure
Study Phase: Early Phase 1
View 5 Less Clinical Trials

113 Total Publications

Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients.
Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients.
Journal: The journal of sexual medicine
Published: March 23, 2025
View All 113 Publications
Similar Doctors
Distinguished in Salpingo-Oophorectomy
Dr. Melissa K. Frey
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Distinguished in Salpingo-Oophorectomy
Dr. Melissa K. Frey
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (13.4 miles away)
212-746-7486
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Frey is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New York, New York. Dr. Frey is rated as a Distinguished provider by MediFind in Salpingo-Oophorectomy. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Lynch Syndrome, Salpingo-Oophorectomy, and Oophorectomy.

Distinguished in Salpingo-Oophorectomy
Dr. Douglas A. Levine
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Salpingo-Oophorectomy
Dr. Douglas A. Levine
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
1275 York Ave, 
New York, NY 
 (13.5 miles away)
646-227-3813
Languages Spoken:
English
See accepted insurances

Douglas Levine is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Levine is rated as a Distinguished provider by MediFind in Salpingo-Oophorectomy. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy.

Advanced in Salpingo-Oophorectomy
Dr. Meghna S. Trivedi
Oncology
Advanced in Salpingo-Oophorectomy
Dr. Meghna S. Trivedi
Oncology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (14.0 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Meghna Trivedi is an Oncologist in New York, New York. Dr. Trivedi is rated as an Advanced provider by MediFind in Salpingo-Oophorectomy. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Salpingo-Oophorectomy, and Thrombectomy.

VIEW MORE SALPINGO-OOPHORECTOMY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holcomb's expertise for a condition
ConditionClose
  • Elite
  • Ovarian Cancer
    Dr. Holcomb is
    Elite
    . Learn about Ovarian Cancer.
    See more Ovarian Cancer experts
  • Distinguished
  • Cervical Cancer
    Dr. Holcomb is
    Distinguished
    . Learn about Cervical Cancer.
    See more Cervical Cancer experts
  • Endometrial Cancer
    Dr. Holcomb is
    Distinguished
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
  • Salpingo-Oophorectomy
    Dr. Holcomb is
    Distinguished
    . Learn about Salpingo-Oophorectomy.
    See more Salpingo-Oophorectomy experts
  • Testicular Yolk Sac Tumor
    Dr. Holcomb is
    Distinguished
    . Learn about Testicular Yolk Sac Tumor.
    See more Testicular Yolk Sac Tumor experts
  • Advanced
  • BRCA Positive Breast Cancer
    Dr. Holcomb is
    Advanced
    . Learn about BRCA Positive Breast Cancer.
    See more BRCA Positive Breast Cancer experts
  • HER2 Negative Breast Cancer
    Dr. Holcomb is
    Advanced
    . Learn about HER2 Negative Breast Cancer.
    See more HER2 Negative Breast Cancer experts
  • Lynch Syndrome
    Dr. Holcomb is
    Advanced
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
  • Malignant Mixed Mullerian Tumor
    Dr. Holcomb is
    Advanced
    . Learn about Malignant Mixed Mullerian Tumor.
    See more Malignant Mixed Mullerian Tumor experts
  • Ovarian Carcinosarcoma
    Dr. Holcomb is
    Advanced
    . Learn about Ovarian Carcinosarcoma.
    See more Ovarian Carcinosarcoma experts
  • Sertoli-Leydig Cell Tumor
    Dr. Holcomb is
    Advanced
    . Learn about Sertoli-Leydig Cell Tumor.
    See more Sertoli-Leydig Cell Tumor experts
View All 7 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Holcomb is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Holcomb is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anal Cancer
    Dr. Holcomb is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Breast Cancer
    Dr. Holcomb is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Carcinoid Syndrome
    Dr. Holcomb is
    Experienced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
  • Chronic Familial Neutropenia
    Dr. Holcomb is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.